Researchers have developed a new approach to T cell therapy that is more effective and less toxic than current treatments. This new approach uses bispecific T cell engagers (BITEs)...
The 50th International Congress on Science, Technology, and Technology-based Innovation (STT50) November 27, 2024 The Faculty of Science would like to extend its heartfelt congratulations to our students for...
TTCI Supports Speakers at APHIA 2025 [Bangkok, Thailand] – 21 Nov 2024The Thailand Hub of Talents in Cancer Immunotherapy (TTCI) is proud to support speakers at the Asia-Pacific Histocompatibility...
Researchers from Chulalongkorn University have developed a new weapon against glioblastoma, a notoriously difficult-to-treat brain cancer, in the form of a brand-new antibody. This antibody is a key component...
CD99 is highly expressed in T cell acute lymphoblastic leukemia (T-ALL), a type of cancer. One promising treatment involves a mouse monoclonal antibody against CD99 called mAb MT99/3, which...
A new humanized antibody, derived from a mouse antibody, has been engineered to target CD99, a protein overexpressed in T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL). The...
Image by ChulalongkornHospital New options for cancer treatment with immunotherapy. Oct 28, 2024 🩺✨ Understanding NK Cells: A Potential Cancer Treatment ✨🩺 Summary from Dr. Kamit Supapipat at Cellular...
Innovations and Networks in Immunotherapy: Bridging Academia and Clinical Applications! Date: December 18, 2024Time: 8:30 AM – 5:00 PMVenue: Chiang Mai University Don’t miss the “Innovations and Networks in...
